^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Gastric Adenocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Margenza (margetuximab-cmkb) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Ann Oncol
    Title:

    Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

    Published date:
    10/09/2018
    Excerpt:
    HER2+, PD-L1-unselected, 2nd line GEA pts post T progression received Margetuximab (M)…+ Pembrolizumab (P)...ORR was 5 of 8 (62.5%) in ERBB2 amplified/PD-L1+ pts.
    DOI:
    10.1093/annonc/mdy282.046
    Trial ID:
    NCT02689284